Do anticholinergic medications (e.g., diphenhydramine, scopolamine, benztropine, oxybutynin, trihexyphenidyl) lower the seizure threshold and increase seizure risk in patients with epilepsy?

Anticholinergics and Seizure Threshold

Yes, anticholinergic medications can lower the seizure threshold and increase seizure risk, but the actual clinical risk varies significantly by specific agent and clinical context. The FDA specifically warns that scopolamine can cause seizures and seizure-like activity, and this risk must be weighed against benefits before prescribing to patients with epilepsy or seizure risk factors 1.

Evidence from FDA Drug Labeling

The scopolamine transdermal system FDA label explicitly states: "Seizures and seizure-like activity have been reported in patients receiving scopolamine. Weigh this potential risk against the benefits before prescribing scopolamine transdermal system to patients with a history of seizures, including those receiving anti-epileptic medication or who have risk factors that can lower the seizure threshold" 1. This represents the highest-quality regulatory guidance available and should directly inform clinical decision-making.

Clinical Risk Assessment

When considering anticholinergic use in patients with epilepsy:

Risk stratification by agent:

• Higher concern agents: Scopolamine has documented FDA warnings for seizure risk 1
• General anticholinergics: The class effect exists but varies by specific medication, dose, and patient factors

Patient-specific risk factors to evaluate:

• Active epilepsy or history of seizures
• Current antiepileptic drug therapy
• Other conditions that lower seizure threshold
• Concurrent use of other seizure-threshold-lowering medications
• Dose and duration of anticholinergic exposure

Evidence from Clinical Practice

Research demonstrates a more nuanced picture than blanket avoidance. A retrospective study of 57 epilepsy patients treated with psychotropic medications (which often have anticholinergic properties) found that during treatment, seizure frequency actually decreased in 33% of patients, remained unchanged in 44%, and increased in only 23% 2. Mean seizure frequency was not statistically different between pre-treatment and treatment periods, supporting that these medications can be safely used when introduced slowly at low to moderate doses 2.

Practical Clinical Approach

When anticholinergics are necessary in patients with epilepsy:

1. Start low, go slow: Use the lowest effective dose with gradual titration 3, 4
2. Monitor closely: Watch for breakthrough seizures, especially during dose escalation
3. Avoid polypharmacy: Minimize concurrent use of multiple seizure-threshold-lowering agents 4, 5
4. Optimize antiepileptic therapy: Ensure baseline seizure control is maximized before adding anticholinergics
5. Consider alternatives: For scopolamine specifically, evaluate if non-anticholinergic antiemetics are viable options given the explicit FDA warning

Important Caveats

The dose-dependent nature of seizure risk is critical 4. Most documented seizures with anticholinergics occur with:

• Overdose situations (seizure risk rises to 4-30%) 4
• High therapeutic doses
• Rapid dose escalation
• Combination with other pro-convulsant medications

Drug-induced seizures account for approximately 6.1% of first-occurring seizures 5, making this a clinically relevant consideration but not an absolute contraindication when medications are used judiciously.

The evidence supports that anticholinergics can be used in epilepsy patients when clinically necessary, but require careful patient selection, conservative dosing strategies, and vigilant monitoring—particularly for agents like scopolamine with explicit FDA seizure warnings 1, 2, 3.